Uncovering the pathophysiology and vulnerability of minimal residual disease persisting under venetoclax in patients with chronic lymphocytic leukemia
People
(Responsible)
Additional information
Start date
14.11.2022
End date
13.02.2024
Duration
15 Months
Funding sources
CLL Global Research Foundation
Status
Ended
Category
